|
| |
| | Valganciclovir effective induction, maintenance therapy for CMV retinitis |
 | | Oral valganciclovir, the authors conclude, appears to be a convenient and effective treatment for induction and long-term maintenance of AIDS patients with CMV retinitis. | | | The proportion of patients in each arm with a "satisfactory" response to induction treatment was also similar--47 of 61 ganciclovir-treated subjects (77%) and 46 of 64 valganciclovir-treated subjects (71.9%). | | | Valganciclovir effective induction, maintenance therapy for CMV retinitis |
|
http://www.aidsmeds.com/news/20020411clin008.html
(422 words)
|
|
| |
| | MedlinePlus Drug Information: Valganciclovir (Systemic) |
| | Before you begin treatment with valganciclovir, you and your doctor should talk about the good this medicine will do as well as the risks of using it. | | | Children—Studies on this medicine have been done only in adult patients, and there is no specific information comparing use of valganciclovir in children with use in other age groups. | | | This is to make sure the medicine is fully absorbed into the body and will work properly. |
|
http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/500289.html
(1296 words)
|
|
| |
| | The Body: Advances in Treating CMV |
| | This is the first oral drug shown to be as effective as standard IV therapy for treating this condition. | | | A large study is planned to look at the effectiveness of preventive CMV treatment with valganciclovir. | | | A new oral drug, valganciclovir, shows effectiveness in treating CMV. |
|
http://www.thebody.com/pinf/aug00/cmv.html
(531 words)
|
|
| |
| | PharmaCare - HIV Headline News Last Updated: 2001-02-27 17:37:55 EST : 's valganciclovir for AIDS-related eye ... |
| | Roche's study, which involved a "direct comparison with the standard of care" plus pharmacokinetic data, was sufficient to support the drug's efficacy for CMV maintenance therapy, she told the committee. | | | In a 12 to 1 vote, the Antiviral Drugs Advisory Committee agreed that valganciclovir is safe and effective as induction therapy for CMV. | | | The therapy has triggered a "real paradigm change" in the way drugs for AIDS-related conditions are studied, noted panel chair Dr. Roger Pomerantz, professor at Philadelphia-based Thomas Jefferson University. |
|
http://www.stadtlander.com/reuters/aids/320728110199.html
(678 words)
|
|
| |
| | The Body: Valganciclovir: A New Treatment for Cytomegalovirus Retinitis |
| | Statistically, the study was not a traditional head-to-head comparison (comparing two drugs with each other), but a noninferiority study (proving that one medication is not inferior to another). | | | After the four-week induction phase, all participants received maintenance therapy with open-label valganciclovir (900 mg daily). | | | In the Roche WV 15376 study, approximately 20% participants experienced a grade 3 or 4 adverse event by week 4. |
|
http://www.thebody.com/sfaf/winter02/valganciclovir.html
(1670 words)
|
|
| |
| | valganciclovir, Eastern Carolina |
| | After taking valganciclovir, it is converted in the body to ganciclovir. | | | Your pharmacist has additional information about valganciclovir written for health professionals that you may read. | | | Continue to take valganciclovir and talk to your doctor if you experience |
|
http://www.uhseast.com/115918.cfm
(1413 words)
|
|
| |
| | TAG: Roche's valganciclovir is recommended for approval |
| | When it came to the question of valganciclovir's effectiveness as maintenance, I informed the ADAC that most CMV drugs were approved for induction and maintenance therapy using an immediate versus deferred trial design. | | | I wondered if some of the ophthalmologists really knew HIV clinical care and understood the entire HIV-positive patient, not just his or her eyes. | | | A source close to the Division told me the hearing was needed because: 1) only one trial of 160 patients was being used for efficacy analysis; and 2) the sponsor was requesting an indication for CMV induction and maintenance therapy but only had efficacy data from the 4-week randomized valganciclovir vs. IV ganciclovir induction phase. |
|
http://www.aidsinfonyc.org/tag/comp/valg.html
(1033 words)
|
|
| |
| | Clinical Trial: Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma |
| | PURPOSE: This clinical trial is studying how well valganciclovir works in treating patients with classic non-HIV-associated Kaposi's sarcoma. | | | Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma | | | Clinical Trial: Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma |
|
http://www.clinicaltrials.gov/ct/show/NCT00096538;jsessionid=AFB7F194F31EC48F7C1DEDD4E5E7BE3E?order=8
(566 words)
|
|
| |
| | VALGANCICLOVIR |
| | Maintain your regular visits and inform your doctor of new medical problems that develop while you are taking valganciclovir. | | | Inform your doctor and pharmacist of all prescribed and non-prescribed drugs you are taking. As well, you should inform them of natural products you are taking. | | | Do not stop taking this drug without checking with your doctor first, even if you begin to feel better. |
|
http://www.tthhivclinic.com/FactSheets/html/VALGANCICLOVIR.html
(788 words)
|
|
| |
| | Project Inform - March 9, 2001 Valganciclovir recommended for approval |
| | Valganciclovir is an improved oral formulation of ganciclovir. | | | However, maintenance therapy usually requires for the drug to be given lifelong. | | | Clinical studies show that valganciclovir is as effective as the intravenous (injection into the vein) form of the drug, which is commonly used to treat CMV disease. |
|
http://www.projinf.org/news/01_03valgan.html
(276 words)
|
|
| |
| | Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and ... |
| | DESIGN AND PARTICIPANTS: The study was an open-label, randomised, 4-way crossover, dose-ranging pharmacokinetic study, conducted in 39 patients who were HIV- and CMV-seropositive. | | | As induction therapy must be given intravenously, an oral formulation which could be used for induction would offer significant benefits. | | | This suggests that oral valganciclovir may be suitable in many circumstances currently requiring intravenous ganciclovir, allowing for more convenience in the management of patients with CMV retinitis by utilising a 2 or 4 tablet daily regimen to cover all phases of treatment. |
|
http://www.aegis.com/aidsline/2000/jan/A0010840.html
(700 words)
|
|
| |
| | VALGANCICLOVIR Drug and Prescription Information, Side Effects, Use, and Dosage |
| | Your doctor will tell you how much of this medicine to take and how often. | | | Ask your doctor or pharmacist before using any other medicine, including over-the-counter medicines, vitamins, and herbal products. | | | VALGANCICLOVIR (Oral) (Tablet) is used for the Treatment |
|
http://www.healthdigest.org/Tylenol-w/VALGANCICLOVIR-(Oral)-(Tablet)_7195_PRO.php
(538 words)
|
|
| |
| | Valganciclovir - Resources from Educational and Academic Institutions |
| | UM CCC - Search for Clinical Trial: Protocol Title: A Phase III Multicenter Study of Valganciclovir for Prevention of | | | MedlinePlus Drug Information: Drugs beginning with UV: Systemic) USP DI; Valadol MedMaster - Acetaminophen; Valcyte USP DI - Valganciclovir | | | The efficacy of oral valganciclovir for the treatment of acute CMV |
|
http://mark.mongabay.com/medications/academic/Valganciclovir.html
(809 words)
|
|
| |
| | New Treatment Guidelines for Opportunistic Infections Recommend Valganciclovir for AIDS-related CMV Retinitis |
| | Among patients with peripheral lesions that are not immediately sight-threatening, oral valganciclovir is preferable to the ganciclovir intraocular implant, intravenous ganciclovir, or intravenous foscarnet because of its greater ease of administration and lack of surgical or catheter-associated complications. | | | However, any of the treatment regimens can be chosen because epidemiologic studies and clinical trials have not demonstrated substantially reduced rates of loss of visual acuity among patients treated with the ganciclovir implant compared with those treated with systemic therapies. | | | The choice of initial therapy for CMV retinitis should be individualized based on the location and severity of the lesion(s), the level of underlying immune suppression, and other factors such as concomitant medications and ability to adhere to treatment. |
|
http://www.hivandhepatitis.com/recent/ois/cmv/020205_c.html
(933 words)
|
|
| |
| | valganciclovir |
| | ...on acyclovir.1 Further results from the multicentre case-control study showed that patients treated with gancicolovir, of which Valcyte (valganciclovir) is a... | | | School of Medicine has found that at least three months of therapy with a single daily dose of the antiviral medication Valcyte (valganciclovir HCl tablets... | | | Resources from the National Cancer Institute on valganciclovir: |
|
http://www.cancer-help.org/cancer/0604/valganciclovir.html
(310 words)
|
|
| |
| | the Drug Monitor- Valganciclovir / Valcyte - Nasr Anaizi, PhD |
| | Valganciclovir is contraindicated in patients with hypersensitivity to ganciclovir or valganciclovir. | | | Michael M. regarding approval of HOFFMANN-LA ROCHE'S valganciclovir for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. | | | The FDA approved indication for valganciclovir is the treatment of CMV retinitis in AIDS patients. |
|
http://www.thedrugmonitor.com/valganciclovir.html
(667 words)
|
|
| |
| | VALGANCICLOVIR- ORAL |
| | Do not start or stop any medicine without doctor or pharmacist approval. | | | Valganciclovir is also used to prevent CMV disease in certain transplant patients (i.e., kidney-pancreas, heart). | | | USES: Valganciclovir is an antiviral medication used to treat people with immune system problems (e.g., AIDS) who have a serious eye infection (cytomegalovirus or "CMV" retinitis). |
|
http://www.personalmd.com/drgdb/4279.htm
(959 words)
|
|
| |
| | Valcyte, Valganciclovir, side effects, drug interactions, overdose, dosage |
| | If you suspect an overdose, seek medical attention immediately. | | | Valcyte tablets are used in the treatment of an eye disease called cytomegalovirus (CMV) retinitis, one of the many infections that take hold when the immune system is undermined by AIDS. | | | Valcyte, Valganciclovir, side effects, drug interactions, overdose, dosage |
|
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/val1584.shtml
(703 words)
|
|
| |
| | valganciclovir |
| | Save up to 85% on prescription and OTC drugs, now with free shipping on everything! | | | JoltSearch has results for valganciclovir and much more! | | | Find results for valganciclovir and anything else you are looking for instantly! |
|
http://www.medcatalog.net/pills/valganciclovir.html
(205 words)
|
|
| |
| | VALGANCICLOVIR |
| | Valganciclovir is an investigational drug that is being studied to prevent the development of cytomegalovirus (CMV) in HIV-infected people with detectable CMV in the bloodstream. | | | Other medications, such as zidovudine (AZT or Retrovir®) may have side effects that are similar to valganciclovir. | | | Some drugs taken together may have interactions that cause illness or impair the effectiveness of the drugs. |
|
http://depts.washington.edu/~actu/drugs/valganciclovir.htm
(524 words)
|
|
| |
| | Valganciclovir: Rx Update: Virtual Hospital |
| | Valganciclovir is indicated for both induction and maintenance therapy in the treatment of CMV retinitis. | | | The dose of valganciclovir should be reduced in patients with decreased renal function. | | | Valganciclovir (Valcyte®), an oral prodrug of ganciclovir, has recently been approved by the FDA for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). |
|
http://www.vh.org/adult/provider/pharmacyservices/RXUpdate/2001/07RXU.html
(292 words)
|
|
| |
| | Drug Shortage Bulletin: Ganciclovir Sodium Injection and Valganciclovir Tablets |
| | Oral ganciclovir is also indicated as an alternative to intravenous ganciclovir for maintenance therapy of stable CMV retinitis in immunocompromised patients, including patients with AIDS. | | | Valganciclovir tablets are not indicated for prevention of CMV disease in liver transplant recipients as clinical trials have not demonstrated its efficacy in this patient group. | | | Use oral valganciclovir whenever possible and reserve intravenous ganciclovir for use when oral therapy is inappropriate or patients cannot take oral therapy. |
|
http://www.ashp.org/shortage/drug.cfm?cfid=4068104&CFToken=88712628&id=1063
(717 words)
|
|
| |
| | Hoffmann-La Roche Submits Application to U.S. FDA for Valganciclovir |
| | A phase III study evaluated the safety and efficacy of valganciclovir for induction therapy in newly diagnosed CMV retinitis patients with AIDS. | | | Valganciclovir is a pro-drug of Roche's existing anti-CMV treatment, CYTOVENE | | | CYTOVENE-IV was approved by the FDA in June 1989 as the first drug for the treatment of CMV retinitis in patients with AIDS. |
|
http://www.rocheusa.com/newsroom/current/2000/pr2000101201.html
(756 words)
|
|
| |
| | Sloan-Kettering - Find a Clinical Trial |
| | Pilot Study of Valganciclovir in Patients with Classic, Non-HIV-Associated Kaposi's Sarcoma | | | Valganciclovir is drug approved to treat cytomegalovirus, a type of herpes virus. | | | Since current treatments for KS do not cure the disease, better treatments are needed. |
|
http://www.mskcc.org/mskcc/html/2270.cfm?peds=No&IRBNO=04-055&team=All&TT=
(210 words)
|
|
| |
| | Valcyte Pharmacology, Pharmacokinetics, Studies, Metabolism - Valganciclovir Hcl - RxList Monographs |
| | The pharmacokinetic properties of valganciclovir have been evaluated in HIV- and CMV-seropositive patients, patients with AIDS and CMV retinitis and in solid organ transplant patients. | | | Valganciclovir is rapidly hydrolyzed to ganciclovir; no other metabolites have been detected. | | | Pediatrics : Valcyte tablets have not been studied in pediatric patients; the pharmacokinetic characteristics of Valcyte tablets in these patients have not been established (see PRECAUTIONS : Pediatric Use). |
|
http://www.rxlist.com/cgi/generic2/valganciclovir_cp.htm
(1046 words)
|
|
| |
| | Stronger form of ganciclovir offers simpler treatment for CMV retinitis in immune-compromised patients |
| | It can be used in conjunction with the eye implant as adjuvant therapy or alone, depending on the patient¹s condition. | | | Researchers have successfully demonstrated the effectiveness of a new experimental oral form of the drug ganciclovir to treat cytomegalovirus (CMV) retinitis, a blinding disorder that is the most common ocular manifestation of AIDS. | | | "A multicenter study is currently underway to evaluate valganciclovir in patients who have documented evidence of CMV in their bloodstreams, but no clinical symptoms." It potentially can help prevent or treat CMV disease in solid organ and bone marrow transplant recipients, whose immune systems are pharmaceutically suppressed to prevent donor organ rejection. |
|
http://www.eurekalert.org/pub_releases/2000-02/EUHS-Sfog-0102100.php
(608 words)
|
|
| |
| | DG DISPATCH - CROI: Oral Valganciclovir As Effective As IV Ganciclovir For CMV Retinitis |
| | Martin said that 77 percent of patients treated with the intravenous compound achieved a satisfactory response, clearing the CMV infection in their eyes, compared with 72 percent of patients taking the oral compound. | | | The new drug, valganciclovir, the oral prodrug of intravenous ganciclovir, is as effective as the intravenous drug in controlling the sight-threatening opportunistic infection, said Dr. Daniel Martin, associate professor of vitreo-retinal surgery and diseases at the Robert Woodruff Health Science Center, Emory University, Atlanta. | | | SAN FRANCISCO, CA -- February 8, 2000 -- Researchers say they have shown for the first time that an oral drug can control cytomegalovirus retinitis in patients with HIV infection. |
|
http://www.docguide.com/dg.nsf/PrintPrint/24638B3254418AAE8525687F00503B1C
(524 words)
|
|
| |
| | Clinical Trial: Valganciclovir in Congenital CMV Infants |
| | A total of 24 patients will be evaluated. | | | Ganciclovir therapy must be administered intravenously and often requires the establishment of a central line in these babies. | | | Valganciclovir, the oral product of ganciclovir, has been developed as a syrup formulation and presents the opportunity to treat longer without the requirement for a central line, but pharmacokinetic data are needed in infants first to assure the correct dose is being utilized. |
|
http://www.clinicaltrials.gov/ct/show/NCT00031434?order=4
(793 words)
|
|
| |
| | 7th Conference - Abstract 231 |
| | Valganciclovir (VGCV) vs. IV Ganciclovir (GCV) as Induction Therapy for Newly Diagnosed Cytomegalovirus (CMV) Retinitis: A Randomized, Controlled Study | | | Conclusion: Valganciclovir, an oral prodrug of ganciclovir with high bioavailability, provides a convenient and effective alternative to IV ganciclovir for the treatment of CMV retinitis. | | | MARTIN*, J. BROWN, and C. ROBINSON for the Roche Valganciclovir Study Group. |
|
http://www.retroconference.org/2000/abstracts/231.htm
(386 words)
|
|
| |
| | Cytomegalovirus -- Facts, Info, and Encyclopedia article |
| | Patients without CMV infection who are given organ transplants from CMV-infected donors should be given prophlyactic treatment with valganciclovir (ideally) or ganciclovir and require regular serological monitoring to detect a rising CMV titre, which should be treated early to prevent a potentially life-threatening infection becoming established. | | | Most infections with CMV are not diagnosed because the virus usually produces few, if any, symptoms and tends to reactivate intermittently without symptoms. | | | Whenever possible, patients without CMV infection should be given organs and/or blood products that are free of the virus. |
|
http://www.absoluteastronomy.com/encyclopedia/c/cy/cytomegalovirus.htm
(2174 words)
|
|
|
